MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call presents a mixed picture. Positive elements include revenue growth, improved gross margins, and strategic plans for sales expansion and operational efficiency. However, concerns arise from increased operating losses, complex integration of ExoDx, and lack of specific guidance details. Q&A insights highlight management's confidence in growth but also reveal uncertainties in achieving financial targets. The market may react cautiously, balancing optimism about strategic initiatives with concerns over financial health and execution risks. Given these factors, a neutral stock price movement is anticipated.

Key Financial Performance

Q4 total billable volume Approximately 38,000 tests, representing total unit growth of 62% versus the prior year quarter. Tissue-based tests decreased by 5%, while liquid-based tests increased by 128%.

Q4 revenues $29.5 million, an increase of 19% compared to $24.7 million for the prior year quarter. Growth attributed to increased test volumes.

Q4 gross profit $18.7 million, an increase of 20% compared to $15.5 million for Q4 2024. Gross margins improved to 63.2% from 62.7%, primarily due to economies of scale.

Q4 operating loss $5.3 million, an increase of 14% compared to $4.6 million for Q4 2024. The increase was driven by higher headcount and operating expenses related to the ExoDx acquisition.

Q4 net loss $8.9 million, an increase of 31% compared to $6.8 million for the prior year. This was driven by a $3.1 million increase in net financial expenses, partially offset by a $1.6 million tax gain.

Q4 adjusted EBITDA Negative $2.1 million compared to negative $1.4 million for Q4 2024, reflecting increased operating expenses.

Cash and cash equivalents as of December 31, 2025 $29 million, reflecting the company's liquidity position.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Menu expansion: Driving balanced growth across tissue and liquid biopsy products, catalyzed by the ExoDx acquisition. Positioned with a best-in-class precision diagnostic menu for prostate cancer.

ExoDx integration: Transitioned all SelectMDx customers to ExoDx, achieving operational efficiencies and eliminating SelectMDx samples.

GPS-ProtecT study: Commenced a landmark study evaluating the predictive power of GPS test in localized prostate cancer patients, aiming to advance its utility in NCCN guidelines.

Market leadership: Positioned as a leader in precision diagnostics for urology, addressing the entire continuum of care for prostate cancer patients.

Revenue growth: Achieved 19% revenue growth in Q4 2025, with total revenue of $107.9 million for the year.

Operational efficiency: Reduced OpEx as a percentage of revenue over the past 3 years, with improved turnaround time for tissue-based patient samples to 5 days or less.

Revenue cycle management: Reorganized under new leadership to enhance access, predictability, and collection across an expanded menu of tests and payers.

Exact Sciences earn-out amendment: Lowered upcoming earn-out payment by close to $20 million and deferred the full amount by an additional year, providing financial flexibility.

Clinical data investment: Committed to advancing clinical data to improve patient outcomes and healthcare economics.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Revenue Adjustment: The company reported a $1 million adjustment to its pre-released revenue estimate due to complexities in consolidating closing processes after the ExoDx acquisition. This indicates potential challenges in financial reporting and integration of acquired businesses.

Operating Loss: Operating loss increased by 14% to $5.3 million in Q4 2025, primarily due to increased headcount and operating expenses related to the ExoDx acquisition. This reflects cost pressures from acquisitions.

Net Loss: Net loss increased by 31% to $8.9 million, driven by higher financial expenses. This highlights financial strain and potential risks to profitability.

Revenue Cycle Management: The company reorganized its revenue cycle management team under new leadership to address access, predictability, and collection challenges. This suggests prior inefficiencies in revenue management.

Tissue-Based Test Volume: Volumes for tissue-based tests decreased by 5% year-over-year, indicating potential challenges in maintaining demand for these products.

Integration of ExoDx: The integration of ExoDx and transitioning of SelectMDx customers to ExoDx created operational complexities, which may pose risks to seamless execution and customer satisfaction.

Clinical Data Investment: The company is investing in clinical data to improve patient outcomes and healthcare economics, which could strain resources if not managed effectively.

Exact Sciences Earn-Out Amendment: The amendment to the Exact Sciences earn-out reduced the payment by $20 million and deferred it by a year, reflecting financial adjustments to manage cash flow and obligations.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Revenue Guidance for 2026: The company expects sustained top-line growth driven by unit growth associated with customer adoption, not dependent on accelerating pricing dynamics.

Operating Profitability: MDxHealth expects to achieve an adjusted EBITDA performance of 10% of revenue by the end of 2026.

Integration of ExoDx Business: The integration of the ExoDx business is expected to be completed by the end of Q1 2026, including transitioning SelectMDx customers to ExoDx and cross-training the sales organization.

Clinical Data Advancements: The company is committed to advancing clinical data to show improvements in patient outcomes and healthcare economics, including the GPS-ProtecT study in collaboration with the University of Oxford.

Landmark Study Presentation: The GPS prompt study results are expected to be presented at the upcoming EAU conference, with the GPS-ProtecT study commencing thereafter.

Strategic Focus: The company will continue disciplined capital allocation, focus on patient and customer experience, and maintain a culture of quality and sustainable growth.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:The tissue ASP was down about $100 quarter-over-quarter. Should we think of that as continued mix shift towards Confirm? Anything happening on rates of denials or anything like that?

A:The assumption is correct. The ASPs reflect a combination of GPS and Confirm, and the mix shift in the quarter can affect the ASP. The Medicare rates for Confirm are $2,000 and for GPS are $3,850. A 2-3 point swing in the mix can impact the ASP.

Q:The EBITDA was lower than expected and cash flow use was higher. Can you explain what's going on and your expectations for cash burn and financing?

A:The lower EBITDA and higher cash flow use are due to the absorption of the ExoDx business acquisition. The company expects significant growth opportunities from this acquisition in 2026 and beyond. They are confident in achieving a 10% EBITDA margin by year-end, with operating expenses declining as a percentage of revenue. The integration process in Q4 and Q1 is expected to clear, and the company is confident in its ability to manage top-line growth and operating expenses.

Q:Your 2026 revenue midpoint implies roughly 28% year-over-year growth. Can you walk us through the assumptions behind that guidance?

A:The company does not guide to product or segment specifics but aims for balanced growth between tissue and liquid. The acquisition of ExoDx is expected to contribute $20 million or more in 2026. The focus is on leveraging the combined customer base of ExoDx and MDxHealth, completing sales integration, and driving adoption of the full menu. The guidance reflects confidence in achieving balanced growth and meeting revenue targets.

Q:After transitioning all customers to ExoDx and mapping the expanded customer base, what do you expect to gain from these efforts?

A:The company expects to leverage the combined customer base of ExoDx and MDxHealth to drive top-line growth. The focus is on cross-selling opportunities and integrating sales efforts. The guidance reflects clear visibility into achieving 20% or greater growth, with confidence in absorbing acquired operating expenses and reaching a 10% EBITDA margin.

Q:Can you provide more detail on where additional operating leverage can be found to achieve a 10% EBITDA margin by 2026?

A:The company plans to hold operating expenses relatively fixed while growing the top line. The increase in OpEx in Q4 was due to the ExoDx acquisition, including headcount and investments in clinical scientific affairs. Gross margins are expected to remain in the low 60s, with aspirations to improve through operating efficiency and pricing strategies.

Q:Review of Unclear Management Responses

A:Management avoided providing specific guidance on product or segment contributions to revenue growth, instead focusing on general goals of balanced growth and leveraging the combined customer base. Additionally, while they expressed confidence in achieving gross margin improvements, they did not provide detailed plans or timelines for reaching higher margins.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

MDXH Transcript

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Unknown2-26

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

Positive11-12

The earnings call presents a generally positive outlook, with a notable decrease in operating and net losses, and strong cash reserves. The Q&A highlights confidence in Exo's future contributions and sustained performance in GPS and Confirm products. Despite some avoidance in addressing ASP declines, the strategic focus on Exo and sales team expansion suggests growth potential. The absence of material negative factors and optimistic guidance point towards a positive stock price movement in the near term.

MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript

Unknown5-14

The earnings call presents a mixed picture: strong revenue growth and improved gross margins are offset by increased net losses and significant financial obligations. The absence of a share repurchase program and concerns over sustaining growth in a competitive market further temper positive sentiment. While management's optimistic guidance and effective market strategy are promising, the lack of specific guidance and financial challenges maintain a neutral outlook for the stock price in the near term.

MDxHealth SA (MDXH) Q4 2024 Earnings Call Transcript

Positive2-26

The earnings call summary shows strong revenue growth and improved financial metrics, with optimistic guidance and raised revenue projections for 2024 and beyond. Despite some risks and uncertainties, the Q&A reveals confidence in the company's strategic direction and market position. The absence of a shareholder return plan is a minor drawback, but overall, the positive financial performance and guidance outweigh potential concerns, suggesting a positive stock price movement.

MDXH Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.